PRACTICAL PEARL: Sexually Transmitted Infections
INTRODUCTION








INITIAL
EVALUATION AND
MANAGEMENT
BY PRIMARY
CARE













WHEN TO REFER





HOW TO REFER
WHAT TO EXPECT
FROM BAYSTATE
CHILDREN’S
HOSPITAL VISIT





The new 2021 STI Treatment Guidelines have been published by the CDC with changes related to
commonly seen STIs: https://www.cdc.gov/std/treatment-guidelines/default.htm
Use of single dose azithromycin has led to antibiotic resistance and does not adequately treat
rectal C. trachomatis (CT) infection in either males or females.
Antibiotic sensitivity to cefixime and ceftriaxone for treatment of N. gonorrhea (NG) remains
good in the US, but resistance has been seen in other parts of the world. Ceftriaxone is the only
medication to reliably treat pharyngeal infection.
Single dose metronidazole is less effective than a one-week course for women for T. vaginalis
(TV) regardless of HIV status. T. vaginalis should be considered in men with persistent/recurrent
urethritis. Avoidance of alcohol is no longer recommended while taking metronidazole.
Pelvic Inflammatory Disease (PID) is a polymicrobial disease which includes infection by
anaerobic bacteria which were not adequately covered by previously recommended first line
treatment.
M. genitalium (MG) is the most common cause of persistent/recurrent urethritis in men. Testing
for MG is recommended for recurrent cervicitis in women and can be considered in PID.
First void urine is the preferred specimen in males when screening for asymptomatic GC, CT, TV,
or symptomatic infection including symptomatic MG.
A clinician or patient self-collected vaginal swab is the preferred specimen in females. Screening
for asymptomatic or symptomatic GC, CT, TV is done with the “blue” Aptima swab. The “orange”
multi-test Aptima swab is used for symptomatic MG and can also be used to simultaneously test
symptomatic GC, CT, TV, MG, yeast, and BV.
Asymptomatic screening for MG is NOT recommended for either males or females since the
consequences of asymptomatic infection are unknown.
CT: One week of doxycycline is now recommended. Single dose azithromycin is reserved for all
pregnant women or those with significant concern for noncompliance. Test of cure is
recommended for all pregnant women and possibly needed for anyone treated with single dose
therapy.
GC: A higher single dose of ceftriaxone (500 mg) as monotherapy is now recommended with 1 g
needed when the weight is >150 kg.
TV: One week of metronidazole is recommended in all women; single dose metronidazole in
men.
PID: Recommendations are for triple drug therapy which includes metronidazole.
MG: One week of doxycycline should be followed by 4 days of azithromycin or one week of
moxifloxacin depending on the results of macrolide resistance testing. If resistance is unknown,
use moxifloxacin.
Immediate test of cure is not needed if first line treatment is used, but repeat testing for CT, GC,
and TV is recommended 3 months post-treatment.
Patients with recurrent STIs, unlikely to be due to reinfection from an untreated partner and
unresponsive to treatment recommendations in the 2021 STI guidelines, should be referred for
further evaluation.
Males with recurrent symptoms of urethritis, but without objective signs of urethritis, should be
referred for further evaluation rather than being prescribed repeated courses of antibiotics
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Referral can be made to Adolescent Medicine or Infectious Diseases.
Evaluation will focus on potential etiology of persistent symptoms including possible antibiotic
resistance as well as determining if further evaluation by another specialty such as urology or
gynecology is indicated.

